title: Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.
abstract: BACKGROUND
  Despite therapeutic approach that combines rituximab-containing chemotherapy, followed or not by autologous stem cell transplantation (auto-SCT), mantle cell lymphoma (MCL) patients experience relapses. Reduced-intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) at time of relapse may represent an attractive strategy.
  
  
  METHODS
  We report a multicenter retrospective analysis. Seventy MCL patients underwent RIC-allo-SCT in 12 centers.
  
  
  RESULTS
  Median age at transplantation was 56 years and median time from diagnosis to transplantation was 44 months. The median number of previous therapies was 2 (range, 1-5) including autologous transplantation in 47 cases. At time of transplantation, 35 patients were in complete remission, 20 were in partial response and 15 in stable disease or progressive disease. The median follow-up for living patients was 24 months. The 2-year event-free survival (EFS) and overall survival (OS) rates were 50% and 53%, respectively. The 1- and 2-year transplant-related mortality rates were 22% and 32%, respectively. The statistical analysis demonstrated that disease status at transplantation was the only parameter influencing EFS and OS.
  
  
  CONCLUSIONS
  These results suggest that RIC-allo-SCT may be an effective therapy in MCL patients with a chemo-sensitive disease at time of transplantation, irrespective of the number of lines of prior therapy. Studies are warranted to investigate the best type of RIC regimen.
authors.affiliation: Division of Hematology, University of Nantes, Hôtel-Dieu, Nantes; Centre de recherches en Cancérologie Nantes/Angers, INSERM, UMR 892, équipe 10, UFR Médecine et Techniques Médicales, Université de Nantes, Nantes; Centre d'Investigation Clinique en Cancérologie (CI2C); Unité de Recherche clinique en onco-hématologie, University of Nantes, Nantes, France. Electronic address: steven.legouill@chu-nantes.fr.
authors.forename: S
authors.initials: S
authors.lastname: Le Gouill
authors.affiliation: Bone Marrow Transplantation Unit, University of Hamburg, Hamburg, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Kröger
authors.affiliation: Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France.
authors.forename: N
authors.initials: N
authors.lastname: Dhedin
authors.affiliation: Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Nagler
authors.affiliation: Division of Hematology, University of Bordeaux, Pessac.
authors.forename: K
authors.initials: K
authors.lastname: Bouabdallah
authors.affiliation: Division of Hematology, University of Lille, Lille.
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
authors.affiliation: Division of Hematology, University of Montpellier, Montpellier.
authors.forename: T
authors.initials: T
authors.lastname: Kanouni
authors.affiliation: University of Grenoble, Grenoble.
authors.forename: C E
authors.initials: CE
authors.lastname: Bulabois
authors.affiliation: Division of Hematology, University of Clermont-Ferrand, Clermont-Ferrand.
authors.forename: O
authors.initials: O
authors.lastname: Tournilhac
authors.affiliation: Hôpital Necker-Enfants malades.
authors.forename: A
authors.initials: A
authors.lastname: Buzyn
authors.affiliation: Hôtel-Dieu, AP-HP, Paris.
authors.forename: B
authors.initials: B
authors.lastname: Rio
authors.affiliation: Division of Hematology, University of Angers, Angers.
authors.forename: M P
authors.initials: MP
authors.lastname: Moles
authors.affiliation: Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Shimoni
authors.affiliation: Bone Marrow Transplantation Unit, University of Hamburg, Hamburg, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Bacher
authors.affiliation: Bone Marrow Transplantation Unit, University of Hamburg, Hamburg, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Ocheni
authors.affiliation: Division of Hematology, University of Bordeaux, Pessac.
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.affiliation: Institut de Cancérologie de l'Ouest, Saint-Herblain.
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
authors.affiliation: Division of Hematology, University of Nantes, Hôtel-Dieu, Nantes; Unité de Recherche clinique en onco-hématologie, University of Nantes, Nantes, France.
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.affiliation: Cancer Registry of Loire-Atlantique and Vendée, Nantes, France.
authors.forename: C
authors.initials: C
authors.lastname: Leux
authors.affiliation: Division of Hematology, University of Nantes, Hôtel-Dieu, Nantes; Centre d'Investigation Clinique en Cancérologie (CI2C); Unité de Recherche clinique en onco-hématologie, University of Nantes, Nantes, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning